Navigation Links
Simcere Pharmaceutical Group to Announce Second Quarter 2010 Financial Results on Thursday, August 12, 2010
Date:8/2/2010

NANJING, China, Aug. 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2010 on Thursday, August 12, 2010, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Thursday, August 12 at 8 p.m. Beijing/Hong Kong time).

    To access the conference call, please dial:

    United States toll-free:    +1.866.277.1184
    International:              +1.617.597.5360
    North China toll-free:      10.800.152.1490
    South China toll-free:      10.800.130.0399
    China toll free / Netcom:   10 800 852 1490
    Hong Kong:                  +852.3002.1672

Please ask to be connected to Q2 2010 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 23060010.

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at http://www.simcere.com .

    Following the earnings conference call, an archive of the call will be
available by dialing:

    United States toll-free:    +1.888.286.8010
    International:              +1.617.801.6888

The passcode for replay participants is: 80027885. The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication, stroke management medication and biopharmaceutical drugs such as vaccines. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .

    Investor and Media Contacts:
     Email: ir@simcere.com

    In Nanjing:
     Frank Zhao
     Chief Financial Officer
     Simcere Pharmaceutical Group
     Tel: +86-25-8556-6666 x8818

    In Beijing:
     Ruirui Jiang
     Brunswick Group
     Tel: +86-10-6566-2256

    In the United States:
     Kate Tellier
     Brunswick Group
     Tel: +1-212-333-3810

    In Hong Kong:
     Joseph Lo Chi-Lun
     Brunswick Group
     Tel: +852-3512-5000


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
2. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
3. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
4. Simceres Diosmectite API Passes EU-GMP Inspection
5. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
6. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
7. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
8. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
9. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
10. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
11. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... April 20, 2017 Eyevensys, a ... first non-viral gene expression technology that enables the safe, ... to address a wide range of ophthalmic diseases, announces ... Healthcare products Regulatory Agency (MHRA) to advance its technology ... ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... ... Bellus Medical, a leader in medical aesthetics, recently acquired ... photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically formulated to ... minimize the appearance of pores – all with minimal downtime and results that ...
(Date:4/25/2017)... ... ... A stressful work environment can hurt the physical and emotional health of employees. ... workplace. The goal of Clearview Resolution Services has always been to help others, starting ... will be shutting down the office early on Fridays. The Clearview team will use ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is ... using Invisalign® in Lutz, FL. With the help of this highly-effective, yet ... with fewer potential complications, more discretion and less pain. , Drs. Sarah Jockin, ...
(Date:4/25/2017)... GA (PRWEB) , ... April 25, 2017 , ... ... their neck and back pain with a reputable physician in their area, announces the ... CRM protects patient information for patients who are looking for reputable physicians to help ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished ... the Outlier Leadership Series, Outliers in Writing, set to publish in summer 2017. ... Medicine at the University of Arizona College of Medicine. He also serves as Medical ...
Breaking Medicine News(10 mins):